Company intelligence / Profile preview
Bicycle Therapeutics
Cambridge, United Kingdombicycletherapeutics.com ↗
- Ownership
- Public · BCYC
- Development stage
- Other
01
Overview
BT8009 advancing to Phase 2/3 registrational trial in metastatic bladder cancer (planned for Q1 2024); BT5528 showing preliminary signs of anti-tumor activity including a partial response; BT7480 in Phase I/II clinical trial
- Therapeutic areas
- OtherOncology
- Modalities
- Bicyclic peptides (Bicycle® molecules)Bicycle Toxin Conjugates (BTCs)Bicycle tumor-targeted immune cell agonists (TICAs)
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Cancer Research UKvarious pharmaceutical partners (specific names not provided)
04
Financials
- Market cap
- $240.3M
- Total revenue
- $72.6M
- Enterprise value
- $-215.4M
Beyond the preview
Go deeper on Bicycle Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bicycle Therapeutics.